The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients has been investigated in previous studies (NCT04190667 and NCT04651920). This study is to investigate the correlation between HRD and the resistance to poly(ADP-ribose) polymerase inhibitors (PARPi) in a Chinese cohort confirmed of epithelial ovarian cancer. The mutated genes, HRD score model and their relationship with the prognosis is the primary endpoint in this study. All enrolled patients will accept PARPi as maintenance therapy after the complete or partial remission of targeted lesions. A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
Study Type
OBSERVATIONAL
Enrollment
400
A multiple panel testing of germline and somatic genes, including BRCA1/2, and HRD score are provided for all participants.
Lei Li
Beijing, Beijing Municipality, China
RECRUITINGProgression-free survival
Progression-free survival after the start of PARPi
Time frame: One year
Overall survival
Overall survival after the start of PARPi
Time frame: One year
Severe adverse events
Severe adverse events after the start of PARPi
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.